Cromwell Holdings’s BridgeBio Pharma BBIO Stock Holding History

Cromwell Holdings’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.61K	Buy	+35	New	+$2.45K	﹤0.01%	796

Other funds holding BBIO

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

WMA

Wealth Management Associates Cherry Hill, New Jersey $362M AUM 33.28% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

FBT

First Bank & Trust Brookings, South Dakota $680M AUM 25.36% 1-Year Est. Return

Cromwell Holdings's BBIO Position: Q2 2026 in Review

Cromwell Holdings opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 35 shares worth $2.61K. The stake represents ﹤0.01% of the portfolio and ranks #796 among its holdings.

56 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Cromwell Holdings held 35 shares of BridgeBio Pharma worth $2.61K as of Q2 2026.
BridgeBio Pharma was a new Cromwell Holdings position in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Cromwell Holdings's portfolio in Q2 2026, its #796 holding.
56 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Cromwell Holdings's 13F filing for Q2 2026, filed 14 Jul 2026.